Lodestone Wealth Management LLC trimmed its position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 3.4% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 481 shares of the company’s stock after selling 17 shares during the quarter. Lodestone Wealth Management LLC’s holdings in Eli Lilly and Company were worth $436,000 at the end of the most recent reporting period.
A number of other large investors have also recently made changes to their positions in LLY. Lipe & Dalton purchased a new position in shares of Eli Lilly and Company during the 4th quarter valued at $26,000. Tidemark LLC bought a new stake in Eli Lilly and Company during the fourth quarter valued at approximately $29,000. Core Wealth Advisors Inc. grew its position in Eli Lilly and Company by 188.2% in the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after acquiring an additional 32 shares in the last quarter. Lynx Investment Advisory purchased a new position in shares of Eli Lilly and Company during the second quarter worth approximately $32,000. Finally, Frank Rimerman Advisors LLC bought a new stake in shares of Eli Lilly and Company in the 4th quarter valued at about $37,000. 82.53% of the stock is owned by institutional investors.
Eli Lilly and Company Trading Up 2.2 %
LLY stock traded up $19.94 during midday trading on Wednesday, reaching $927.99. 1,940,946 shares of the company traded hands, compared to its average volume of 3,092,584. The business has a 50 day moving average of $873.64 and a 200-day moving average of $800.31. Eli Lilly and Company has a 52-week low of $516.57 and a 52-week high of $966.10. The firm has a market capitalization of $881.97 billion, a price-to-earnings ratio of 136.49, a P/E/G ratio of 1.81 and a beta of 0.41. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35.
Eli Lilly and Company Announces Dividend
Insider Activity
In other news, major shareholder Lilly Endowment Inc sold 92,563 shares of the business’s stock in a transaction on Friday, May 24th. The shares were sold at an average price of $809.21, for a total transaction of $74,902,905.23. Following the completion of the sale, the insider now directly owns 98,556,247 shares of the company’s stock, valued at $79,752,700,634.87. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, major shareholder Lilly Endowment Inc sold 92,563 shares of the company’s stock in a transaction on Friday, May 24th. The stock was sold at an average price of $809.21, for a total transaction of $74,902,905.23. Following the completion of the sale, the insider now directly owns 98,556,247 shares in the company, valued at approximately $79,752,700,634.87. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Donald A. Zakrowski sold 750 shares of Eli Lilly and Company stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total transaction of $614,602.50. Following the completion of the transaction, the chief accounting officer now directly owns 7,130 shares in the company, valued at $5,842,821.10. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,214,704 shares of company stock valued at $1,066,841,316. 0.13% of the stock is currently owned by company insiders.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $725.00 to $1,025.00 in a research report on Monday. JPMorgan Chase & Co. lifted their target price on shares of Eli Lilly and Company from $900.00 to $1,000.00 and gave the stock an “overweight” rating in a report on Thursday, July 11th. Berenberg Bank increased their price objective on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research report on Wednesday. Guggenheim lifted their target price on shares of Eli Lilly and Company from $855.00 to $884.00 and gave the stock a “buy” rating in a research report on Monday, August 5th. Finally, BMO Capital Markets upped their target price on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Two investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $948.29.
View Our Latest Research Report on Eli Lilly and Company
Eli Lilly and Company Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Recommended Stories
- Five stocks we like better than Eli Lilly and Company
- Roth IRA Calculator: Calculate Your Potential Returns
- Brinker International’s Price Dip is an Appetizing Entry Point
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- 3 Stocks That Could Beat the September Blues
- How to Use the MarketBeat Stock Screener
- Canopy Growth Stock: Can It Sustain Recent Gains?
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.